依达拉奉联合高压氧治疗颅脑外伤的临床效果

Clinical effect of edaravone combined with hyperbaric oxygen on craniocerebral trauma

目的通过观察脑外伤后患者炎性因子、细胞免疫以及神经功能指标的变化探讨颅脑外伤患者联合应用依达拉奉以及高压氧治疗的临床效果。方法选取2015年3月~2017年3月在我院收治的颅脑外伤患者90例,随机分为对照组和研究组,对照组应用依达拉奉治疗,研究组联合应用高压氧治疗。比较治疗前后的GCS、ADL评分;IL-6、CRP、TNF-α;CD4^+、CD8^+、CD4^+/CD8^+的差异。结果治疗前两组患者的GCS及ADL评分无显著差异(P>0.05),治疗后2周及4周研究组显著高于对照组(P<0.05);治疗前两组患者的IL-6、CRP、TNF-α无显著差异(P>0.05),治疗后2周及4周研究组IL-6、CRP、TNF-α显著低于对照组(P<0.05);治疗前两组患者的CD4^+、CD8^+、CD4^+/CD8^+无显著差异(P>0.05),治疗后2周及4周研究组CD4^+、CD8^+、CD4^+/CD8^+显著高于对照组(P<0.05)。结论依达拉奉联合高压氧治疗颅脑外伤患者,有利于降低炎性因子水平,提高治疗效果。

Objective To observe the clinical effect of combination of edaravone and hyperbaric oxygen in patients with traumatic brain injury by observing the changes of inflammatory cytokines, cellular immunity and neurological function after traumatic brain injury. Methods 90 cases of traumatic brain injury admitted in our hospital from March 2015 to March 2017 were randomly divided into the control group and the study group. The control group was treated with edaravone, and the study group was treated with hyperbaric oxygen therapy. The scores-of GCS and ADL and the differences of IL-6, CRP, TNF-α, CD4^＋, CD8^＋ and CD4^＋/CD8^＋ between the two groups before and after treatment were compared. Results There was no significant difference in GCS and ADL scores between the two groups before treatment （P〉0.05）. The GCS and ADL scores of the study group were significantly higher than those of the control group at 2 weeks and 4 weeks after treatment（P〈0.05）. There was no significant difference in IL-6, CRP and TNF-α between the two groups before treatment （P〉0.05）. The levels of IL-6, CRP and TNF-α in the study group were significantly lower than those in the control group at 2 and 4 weeks after treatment（P〈0.05）. There was no significant difference in CD4^＋, CD8^＋, CD4^＋/CD8^＋ between the two groups before treatment（P〉0.05）. The levels of CD4^＋, CD8^＋ and CD4^＋/CD8^＋ of the observation group were significantly higher than those of the control group at 2 weeks and 4 weeks after treatment（P〈0.05）. Conclusion Edaravone combined with hyperbaric oxygen in the treatment of patients with craniocerebral trauma is conducive to reduce the level of inflammatory cytokines and improve the therapeutic effect.